318 related articles for article (PubMed ID: 26503222)
1. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
Wöllner J; Pannek J
Spinal Cord; 2016 Jan; 54(1):78-82. PubMed ID: 26503222
[TBL] [Abstract][Full Text] [Related]
2. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
Welk B; Hickling D; McKibbon M; Radomski S; Ethans K
Neurourol Urodyn; 2018 Nov; 37(8):2810-2817. PubMed ID: 30168626
[TBL] [Abstract][Full Text] [Related]
3. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
Krebs J; Pannek J
Spinal Cord; 2013 Apr; 51(4):306-9. PubMed ID: 23247012
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study.
Vasudeva P; Prasad V; Yadav S; Kumar N; Saurav K; Prashanth YM; Tyagi V
Neurourol Urodyn; 2021 Feb; 40(2):666-671. PubMed ID: 33410559
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity.
Krhut J; Wohlfahrt P; Pudich J; Kufová E; Borovička V; Bílková K; Sýkora R; Mokriš J; Cífková R; Zachoval R; Zvara P
Int Urol Nephrol; 2021 Jun; 53(6):1089-1095. PubMed ID: 33417146
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.
Krhut J; Borovička V; Bílková K; Sýkora R; Míka D; Mokriš J; Zachoval R
Neurourol Urodyn; 2018 Sep; 37(7):2226-2233. PubMed ID: 29603781
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
9. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients?
Hadiji N; Previnaire JG; Benbouzid R; Robain G; Leblond C; Mieusset R; Enjalbert M; Soler JM
Spinal Cord; 2014 Sep; 52(9):701-5. PubMed ID: 25047051
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review.
Akkoc Y
Spinal Cord; 2022 Oct; 60(10):854-861. PubMed ID: 36085413
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
13. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
14. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
17. Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study.
Krebs J; Pannek J; Rademacher F; Wöllner J
World J Urol; 2021 Feb; 39(2):543-547. PubMed ID: 32322995
[TBL] [Abstract][Full Text] [Related]
18. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
19. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
[TBL] [Abstract][Full Text] [Related]
20. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results.
Gobeaux N; Yates DR; Denys P; Even-Schneider A; Richard F; Chartier-Kastler E
Neurourol Urodyn; 2012 Jun; 31(5):672-6. PubMed ID: 22532256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
